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Abstract 
Purpose: To develop biodegradable, polymeric in situ gels based on sodium alginate and 
hydroxypropyl methylcellulose for intrathecal delivery of ketorolac tromethamine (KT) for effective 
management of pain and inflammation in vertebral fracture.  
Method: Ion activated in situ gels were used as implants and were prepared from sodium alginate and 
hydroxypropyl methylcellulose. The fabricated gels were evaluated for visual appearance, clarity, pH, 
gelling capacity, drug content, viscosity (using Brookfield viscometer), in vitro drug release (using a 
fabricated KC cell) and in vivo analgesic and anti-inflammatory activity (by intrathecal administration of 
in situ gel near the fractured vertebra in a rat model). 
Results: The physicochemical properties (visual appearance, clarity, pH, gelling capacity, drug content 
and viscosity) of in situ gels were acceptable for therapeutic use. KT-loaded gels demonstrated high 
drug encapsulation efficiency (98.3 - 103.3 %). Further, KT-loaded gels exhibited viscosity in the range 
of 1.11 to 6 cps at 50 rpm and shear thinning property (rheology testing). Additionally, the gels 
demonstrated 84.43 to 96.98 % drug release at the end of 12 h. In particular, in situ gels prepared from 
1.2 % alginate/0.4 % HPMC (G7) exhibited excellent analgesic (54.28 %) and anti-inflammatory activity 
(51.6 % inhibition of rat paw edema) in the animal model of vertebral fracture.  
Conclusion: The formulated in situ gels can potentially be used as implants for the treatment of 
patients with vertebral fracture.   
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Vertebral fractures (VF) are common in patients 
suffering from osteoporosis and osteomyelitis 
and lead to severe pain at the fracture site. VF is 
a condition associated with acute back pain and 
may lead to chronic pain and loss of height. 
Upon stress induced by VF, the human body 
transmits alarming signals mediated by 
inflammation. Inflammation, in turn, is mediated 
through a number of chemical factors like 
bradykinin, histamine, prostaglandin and 
interleukin-1. First-line treatment of VF is 
associated with the administration of non-
steroidal anti-inflammatory drugs (NSAIDs) that 
reduce levels of the aforementioned chemical 
mediators, thereby relieving pain and 
inflammation [1-3]. However, complete VF 
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treatment demands prolonged drug release in 
order to provide round-the-clock management of 
pain and inflammation. 
 
As an example, ketorolac tromethamine (KT) is a 
widely used NSAID for the management of 
moderate to severe pain associated with trauma, 
post-operative pain, breakthrough pain of cancer, 
VF as well as spinal injuries and is usually 
administered through oral, intramuscular or 
intravenous routes. KT acts by inhibiting 
cyclooxygenase-1 (COX-1) and COX-2 and has 
been reported to be 800 times more potent than 
aspirin [4-5]. Moreover, unlike narcotic 
analgesics, it is non-addictive and free of any 
respiratory side effects. However, since KT has a 
biological half-life (t½) of 4 to 6 h, its frequent 
dosing is required in order to manage the chronic 
pain for a prolonged period.  
 
Therefore, biodegradable, implantable drug 
delivery systems have been designed to release 
the drug of choice at the target site (for e.g., 
fractured vertebra) for an extended period of 
time. In this regard, various dosage forms or 
delivery systems including surgical implants and 
transdermal drug delivery systems have been 
investigated for prolonged drug release [6-8]. 
However, implantation of the aforementioned 
devices to a target site demands surgical 
intervention [9,10], thereby reducing patient 
compliance. Recently, in situ gel systems have 
received considerable attention since they are in 
liquid state (before administration) and can 
transform into a stiff gel (viscous) format upon 
injection to the body cavity. In situ gel formation 
allows slow drug release, primarily by diffusion 
across the gel matrix. Additionally, in situ gels 
are advantageous in comparison to implantable 
drug delivery systems with respect to ease of 
their administration thereby leading to improved 
patient compliance [11].  
Although a variety of biodegradable polymers 
have been employed for in situ gel formation, this 
study deals with the fabrication of alginate-based 
in situ gels for intrathecal delivery of KT. 
Alginates are naturally occurring anionic 
polysaccharides obtained from marine brown 
algae and consist of two monomeric units; β-D-
mannuronic acid and α-L-guluronic acid. Sodium 
salt of alginic acid (sodium alginate) shows 
gelation properties as a result of crosslinking of 
branched chain structure containing acidic 
contents with multivalent cations such as Ca2+, 
Ba2+, and Al3+ [12-15]. Therefore, dilute aqueous 
solutions of alginate form firm gels upon addition 
of di- and trivalent ions (commonly present in 
simulated biological fluid (SBF)). 
 
The present work deals with the development of 
alginate-based in situ gels for the delivery of KT. 
Intrathecal administration of these in situ gels 
could lead to reduced dosage frequency, 
prolonged drug release and ultimately improved 







Ketorolac tromethamine (KT), sodium alginate 
and hydroxypropylmethyl cellulose were 
purchased from Sigma Chemical (USA). All other 
chemicals were of analytical grade. 
 
Preparation of orthopaedic implants of KT 
 
On the basis of gelling capacity of various 
formulations as performed by hit and trial 
method, the composition of KT loaded in situ gel 




Table 1: Composition of in situ gel formulations 
 
 
   Ingredient 












































































































KT: Ketorolac tromethamine; HPMC: hydroxypropyl methylcellulose 
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Aqueous solutions of different HPMC 
concentrations were prepared by cold method 
and evaluated for gelling capacity and viscosity 
in order to identify the compositions suitable for 
in situ gel systems (Table 1). The alginate 
solutions were prepared by dispersing the 
required amount of sodium alginate in 75 mL 
distilled deionized water with continuous stirring 
until completely dissolved. Further, 
alginate/HPMC solutions were prepared by 
dispersing the required amount of HPMC in the 
desired concentration of sodium alginate with 
continuous stirring until completely dissolved. KT 
was dissolved in hydrochloric acid and the pH 
was adjusted to 6.7. Sodium benzoate was then 
added to the aforementioned solution. Finally, 
the drug solution was added to alginate or 
alginate/HPMC solution under constant stirring 
until a uniform, clear solution was obtained. 
Distilled deionized water was then added to 
make the volume up to 100 mL. The gels were 
finally sterilized by ethylene oxide and stored in 




The clarity of formulated solutions was 
determined by visual inspection under black and 
white background. Since pH is one of the most 
important factors involved in formulation design, 
pH of the prepared formulation was monitored 




The drug content was determined by diluting 1 ml 
of formulation with 10 ml distilled water. This was 
further diluted with distilled water in the ratio 1 to 
10 and the drug concentration was determined at 
232 nm using UV-Vis spectrophotometer. 
 
Viscosity and rheology 
 
The viscosity of polymeric formulations either in 
solution or in gel made with artificial tear fluid, 
was determined using Brookfield viscometer DV 
II+Pro USA. 
 
In vitro release studies 
 
In vitro release of KT from formulations was 
studied using a fabricated KC cell testing 
apparatus. Briefly, a cellophane membrane was 
soaked overnight in freshly prepared dissolution 
medium (phosphate buffer, pH 7.4). The 
membrane was then inserted between the donor 
and receiver compartment of KC cell, following 
which 1 mL formulation was pipetted into this 
assembly. A 10 mL dissolution medium was 
maintained at 37 ± 1 oC so that the membrane 
just touched the receptor medium surface. 
Dissolution medium was stirred with magnetic 
stirrer. Aliquots (each of 1 mL volume) were 
withdrawn at regular intervals and replaced by an 
equal volume of the receptor medium. The 
aliquots were then diluted with the receptor 
medium and analysed by UV spectrophotometer 
at 232 nm. 
 
In vivo study 
 
Healthy male Wistar rats (200 - 250 g) were used 
for the study. They were kept in cages under 
standard environmental conditions of light and 
temperature and were allowed free access to 
drinking water and standard diet. In vivo studies 
were carried out in compliance with Directive 
2010/63/EU on the Handling of Animals Used for 
Scientific Purposes [16]. 
 
In vivo analgesic activity  
 
Acute analgesic response by KT was assessed 
by acetic acid induced writhing method in rats. 
For this, rats were divided in three groups of six 
each. The first group served as the control group, 
wherein the rats received an appropriate volume 
of 2 % Tween 80 only, p.o. To the second (test) 
group, KT loaded gel (G7) was injected 
intrathecally near the fractured vertebra (3.50 
mg/kg body mass). The third group was treated 
with standard ketorolac tablet (0.33 mg/kg body 
mass) as slurry p.o. Three hours after treatment, 
the vertebra was fractured (around C2 and C4) 
by surgery. Total number of writhes, which was a 
parameter of chemically induced pain (i.e., 
constriction of abdomen, turning of trunk and 
extension of hind legs), was counted for a period 
of 20 min. The analgesic effect was expressed 
as percentage reduction of writhes in comparison 
with the control group. 
 
In vivo anti-inflammatory study 
 
In the next set of experiments, in vivo anti-
inflammatory study was performed using the 
standard carrageenan induced hind rat paw 
edema model [14]. For this, rats were divided 
into control, standard and test groups of six 
animals each. Before treatment, initial paw 
volumes of all animals were measured using a 
mercury plethysmometer. Control group was 
given no drug, however, the rats received 2 % 
xanthan gum orally in an appropriate volume. 
Standard group received free ketorolac (0.33 
mg/kg body mass, p.o.), while the test groups 
received KT loaded G7 gels (3.50 mg/kg body 
mass), intrathecally. In order to induce paw 
edema, one hour following gel/drug 
administration, all rats were injected (subplantar 
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route) with 0.1 mL of a 1 % w/v homogeneous 
suspension of carrageenan (in double-distilled 
water) in the right paw. The hind paw volume 
was measured immediately (0 h) as well as at 
different time intervals, using a plethysmometer 
and expressed as percentage edema relative to 
the initial hind paw volume. The relative increase 
in paw volume was determined by measuring the 
paw volume after 3 h following the carrageenan 
administration. The percentage inhibition of 
edema, as an indicator of anti-inflammatory 





The results in this study are expressed as mean 
± standard deviation (SD) and statistical analysis 
was performed by Student’s t-test using Origin 
1.5 (OriginLab Corporation, USA). A probability 





In the first set of experiments, ion activated in 
situ gels were prepared using the cold method. 
Only those formulations that gelled 
instantaneously (< 1 min) following their contact 
with SBF were selected for further study (Table 
1).  
 
Physicochemical characterization of the gels 
 
Visual inspection revealed the formation of a 
translucent matrix following incubation of the 
formulations with SBF. The prepared gels were 
transparent at all pH values. Further, pH of all 
formulations was in acceptable range (Table 2) 
and the clarity of all formulations was 
satisfactory. Further, the formulations were slight 
yellow in colour.  
 
The drug content was found to be in the 
acceptable range for all formulations. Percentage 
drug content in all formulations was in the range 
of 98.3 - 103.3 % indicating uniform drug 
distribution in the studied formulations. 
 
Viscosity and rheological properties of KT 
loaded gels  
 
 
Three best formulations (G2, G4 and G7) were 
evaluated for viscosity using Brookfield 
viscometer DV II+Pro. The formulations exhibited 
pseudo-plastic rheology as evidenced by shear 
thinning and increase in shear rate as a function 
of angular velocity. The viscosity was however 
found to be dependent on polymeric content of 
the formulations and followed the order, 
G7>G2>G4. 
 
Table 2: Physicochemical evaluation of KT loaded gels 
 
 Code Appearance Clarity pH Drug 
content (%) 
 G1 Transparent Clear 6.4 100.20 
 G2 Transparent Clear 6.7 102.12 
 G3 Transparent Clear 6.5 100.00 
 G4 Transparent Clear 6.7 103.10 
 G5 Transparent Clear 6.6 104.80 
 G6 Transparent Clear 6.3 101.15 
 G7 Transparent Clear 6.7 99.10 
 G8 Transparent Clear 6.3 102.50 
 







Viscosity of formulations (cps) 













10 7.20 22.9 5.06 18.09 10.5 24.9 
20 6.00 21.9 4.12 17.90 9.05 23.7 
30 5.00 20.5 3.00 16.50 8.12 22.7 
40 4.05 19.2 2.02 15.20 7.05 21.7 
50 3.00 18.0 1.11 14.00 6.00 20.6 
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Table 4: In vivo analgesic and anti-inflammatory activity of KT loaded gel 
 
Drug Oral dosea 
(mg/kg) 
Analgesic Activity Anti-inflammatory activity 
No. of writhes 
b 
Analgesia (%) Paw volume 





- 70±2 - 0.95 ± 0.04 - 
KT (standard) 0.33 26±2 d 62.85 0.42±0.01 d 55.8 
G7 3.4 32±1 d 54.28 0.46±0.02 d 51.6 
aDose equimolar to the parent drug calculated on the basis of drug contents; b Mean ± SEM, n = 6; c Change in 
paw volume 3 h after carrageenan injection.; dp< 0.05 vs. control 
 
In-vitro drug release  
 
In vitro drug release studies were carried out for 
all formulations using simulated biological fluid 
(SBF) as the dissolution medium. It was found 
that the percentage drug release was 88.67, 
86.59, 89.43, 88.28, 97.12, 96.98, 84.43 and 
91.38 % for the formulation G1, G2, G3, G4, G5, 
G6, G7 and G8, respectively at the end of 12 h. 
In order to gain insight into drug release 
mechanism from ion activated in situ gels, the 
release data was subjected to different modes of 
data treatment. The results indicated a zero 
order drug release profile from alginate based in 
situ gels, potentially as a result of diffusion from 
the gel matrix.  
 
In vivo analgesic and anti-inflammatory 
activity of KT loaded gels 
 
On the basis of physiochemical properties, 
rheological properties and in vitro release profile, 
formulation G7 was selected for determining the 
in vivo analgesic and anti-inflammatory potential 
of KT-loaded biodegradable implants on Wistar 
rats (Table 4). 
 
Analgesic and anti- inflammatory activities of KT 
loaded G7 gels were found to be 54.28 % and 
51.6 % respectively, and the effect was 
comparable to that of the free drug. The anti-
inflammatory activity was presented in terms of 
inhibition (%) of paw edema using the standard 
carrageenan induced hind rat paw edema model. 
Taken together, the results of this study 
demonstrated the potential of KT loaded in situ 
gels (G7) in VF treatment due to high drug 
content, good rheological properties as well as 





Biodegradable polymers have shown potential as 
drug delivery systems in the form of implants and 
devices for bone repair. Apart from being non-
mutagenic and non-cytotoxic, biodegradable 
polymers are metabolized in the body and 
eliminated by normal physiological pathways 
[17,18]. Of the various fabrication systems 
available, in situ gels show potential for local as 
well as systemic controlled drug delivery systems 
[19-21]. Further, since intrathecal KT (free drug) 
pre-treatments have been reported to reduce the 
spinal cord ischemic and VF injuries [22], this 
study employed in situ gels for intrathecal KT 
administration due to the disadvantages 
associated with the administration of free KT 
(e.g., poor drug stability, reduced half-life, 
frequent administration and hence reduced 
patient compliance). 
 
Sodium alginate was used for the fabrication of 
ion activated in situ gels due to the property of its 
aqueous solutions to transform into stiff gels 
through ionic gelation in presence of divalent 
cations of SBF (Ca2+). Further, alginate-based in 
situ gels have been reported to preserve their 
integrity without undergoing dissolution or 
erosion for prolonged period of time [23]. 
Moreover, the method used for fabrication of 
alginate-based in situ gels in the present study 
was simple and reproducible. Only those 
formulations were selected that demonstrated 
satisfactory attributes in terms of gelling capacity 
in the pre-formulation studies. 
 
The initial drug release pattern from alginate 
based in situ gels was characteristic of 
hydrophilic matrices. This initial fast release of 
KT could be attributed to the fact that alginate 
gels were formulated in water and hence the 
polymer was completely hydrated. Incubation in 
SBF resulted in gelation and formation of a pre-
hydrated matrix wherein hydration and water 
penetration no longer limited the drug release 
thereby leading to an apparent diffusion based 
controlled release. In particular, there was 11.19 
% release of KT from formulation G7 after 0.5 h, 
and 84.43 % after 8 h, and the drug release 
continued to rise thereafter. 
 
Following comparison with other formulations, 
G7 (based on 1.2 % alginate/0.4 % HPMC) 
showed better ability to retain KT and hence was 
Cao et al 
Trop J Pharm Res, January 2016; 15(1): 10  
 
chosen for further studies. Additionally, the 
chosen formulation demonstrated analgesic as 
well as anti-inflammatory activity. Taken 
together, results of this study suggest that the 
alginate/HPMC aqueous system show potential 
as an in situ gel-forming system for intrathecal 




This work involved the development of alginate-
based in situ gels for the delivery of KT. The gels 
demonstrated high drug encapsulation efficiency 
and can be employed for continuous and 
extended release of KT. The gels also exhibit 
analgesic and anti-inflammatory activity in vivo 
thereby indicating the potential for round-the-
clock management of pain and inflammation in 
patients with VF. However, further studies are 
required to determine the suitability of the 




Protocols for in vivo studies were approved by 
the Animal Care and Use Committee of The First 
Affiliated Hospital of Xinxiang Medical University, 
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